Unit

UNIT 14.23 Patient-Derived Models of Human Breast Cancer: Protocols for In Vitro and In Vivo Applications in Tumor Biology and Translational Medicine

  1. Yoko S. DeRose1,5,
  2. Keith M. Gligorich2,5,
  3. Guoying Wang1,
  4. Ann Georgelas3,
  5. Paulette Bowman3,
  6. Samir J. Courdy4,
  7. Alana L. Welm1,
  8. Bryan E. Welm2

Published Online: 1 MAR 2013

DOI: 10.1002/0471141755.ph1423s60

Current Protocols in Pharmacology

Current Protocols in Pharmacology

How to Cite

DeRose, Y. S., Gligorich, K. M., Wang, G., Georgelas, A., Bowman, P., Courdy, S. J., Welm, A. L. and Welm, B. E. 2013. Patient-Derived Models of Human Breast Cancer: Protocols for In Vitro and In Vivo Applications in Tumor Biology and Translational Medicine. Current Protocols in Pharmacology. 60:14.23:14.23.1–14.23.43.

Author Information

  1. 1

    Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah

  2. 2

    Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah

  3. 3

    Tissue Resource and Applications Core Shared Resource Facility, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah

  4. 4

    Research Informatics, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah

  5. 5

    These authors contributed equally to this work.

Publication History

  1. Published Online: 1 MAR 2013

Abstract

Research models that replicate the diverse genetic and molecular landscape of breast cancer are critical for developing the next-generation therapeutic entities that can target specific cancer subtypes. Patient-derived tumorgrafts, generated by transplanting primary human tumor samples into immune-compromised mice, are a valuable method to model the clinical diversity of breast cancer in mice, and are a potential resource in personalized medicine. Primary tumorgrafts also enable in vivo testing of therapeutics and make possible the use of patient cancer tissue for in vitro screens. Described in this unit are a variety of protocols including tissue collection, biospecimen tracking, tissue processing, transplantation, and three-dimensional culturing of xenografted tissue, which enable use of bona fide uncultured human tissue in designing and validating cancer therapies. Curr. Protoc. Pharmacol. 60:14.23.1-14.23.43. © 2013 by John Wiley & Sons, Inc.

Keywords:

  • breast cancer;
  • tumorgraft;
  • organoid;
  • 3D culture;
  • Matrigel;
  • EHS matrix;
  • biospecimen;
  • tissue repository;
  • tissue collection;
  • xenograft